Current ESMO [1], NICE (UK) [8], and Australian [83] guidelines do not recommend routine BRAF testing in non-metastatic CRC patients, except in MSI-H CRC to distinguish between sporadic and familial (Lynch syndrome) cases. The gene discussed is BRAF; the disease is colorectal carcinoma.